Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes: A randomized, 24-week, open-label, controlled trial (STOP-OB)

Kitazawa T, Seino H, Ohashi H, Inazawa T, Inoue M, Ai M, Fujishiro M, Kuroda H, Yamada M, Anai M, Ishihara H.Diabetes Obes Metab. 2020 09;22(9):1659-1663. doi: 10.1111/dom.14059